Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 27, 2026
Reporting period
Not applicable
Filed with the SEC
Aug 28, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-374352
Filed / recorded
Aug 28, 2026, 8:10 PM UTC
Added to OQRO
Oct 8, 2026, 2:06 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Kalaris Therapeutics, Inc.
Issuer CIK
1754068
Ticker
KLRS
Reporting person
Amy O'leary Vandekop
Relationship
Officer
Officer title
VP, Corporate Controller
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Aug 27, 2026
Transaction code
A
Shares / units
10,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
10,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.